Edgewise Therapeutics, Inc.
EWTX
Peringkat dalam Saham
#3979
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Harga Saham
$38.12
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$4.10B
Perubahan (1 hari)
2.50%
Perubahan (1 tahun)
147.69%
Negara
US
Perdagangan Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Jumlah saham beredar untuk Edgewise Therapeutics, Inc. (EWTX)
Jumlah saham beredar per June 2026: 107.67M
Menurut laporan keuangan terbaru dan harga saham Edgewise Therapeutics, Inc., jumlah saham beredar saat ini adalah 107.67M. Pada akhir December 2023, perusahaan memiliki 63.72M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Edgewise Therapeutics, Inc. (EWTX) dari 2019 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 107.67M | 16.51% |
| 2024 | 92.41M | 45.02% |
| 2023 | 63.72M | 18.90% |
| 2022 | 53.59M | 8.27% |
| 2021 | 49.50M | 0.58% |
| 2020 | 49.22M | 0.00% |
| 2019 | 49.22M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | 135.81% |
US
|
|
| 396.00M | 267.79% |
US
|
|
| 478.91M | 344.80% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -42.24% |
NL
|
